SCHEMBL12426787

SCHEMBL12426787

CC(C)(C)OC(=O)N1CCC(NC(=O)c2ccc(N)c(C(F)(F)F)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 3/20 0.58
HDAC6 Q9UBN7 2/20 0.52
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
TAS1R2 Q8TE23 1/20 0.48
USP30 Q70CQ3 3/20 0.48
EPHX1 P07099 1/20 0.47
RIPK1 Q13546 1/20 0.46
KMT2A Q03164 1/20 0.46
PARP1 P09874 1/20 0.46
EPHX2 P34913 1/20 0.46
RIPK2 O43353 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
ALDH1A1 P00352 2/20 0.45
BRD4 O60885 1/20 0.45
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12427455 0.87 HDAC4 (0.55) HDAC4HDAC6USP30EPHX1KMT2A
SCHEMBL12426676 0.86 HDAC4 (0.53) HDAC4USP30EPHX1KMT2APARP1
SCHEMBL3546076 0.84 HDAC4 (0.52) HDAC4HDAC6USP30EPHX1KMT2A
SCHEMBL12426675 0.84 HDAC4 (0.52) HDAC4USP30EPHX1KMT2APARP1
SCHEMBL13575561 0.83 TAS1R3 (0.55) HDAC4HDAC6TAS1R3TAS1R1TAS1R2
SCHEMBL12426680 0.83 HDAC4 (0.61) HDAC4HDAC6USP30EPHX1KMT2A
SCHEMBL13158349 0.83 ALDH1A1 (0.60) EPHX2CA12CA1CA2CA9
SCHEMBL20553260 0.83 HDAC4 (0.54) HDAC4HDAC6TAS1R3TAS1R1TAS1R2
SCHEMBL12426369 0.82 NPSR1 (0.50) HDAC4USP30EPHX1ALDH1A1NPC1
SCHEMBL18050965 0.81 USP30 (0.58) HDAC4USP30EPHX1KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003785-B2 Halo-substituted pyrimidodiazepines TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) 2011-08-23 US disclosed
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-24 US disclosed
WO-2009153197-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318408-A1 HALO-SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 HDAC4 798/4885HDAC6 147/4885TAS1R3 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.